India markets closed

  • BSE SENSEX

    49,591.32
    -154.89 (-0.31%)
     

  • Nifty 50

    14,834.85
    -38.95 (-0.26%)
     

  • USD/INR

    74.7100
    +0.1490 (+0.20%)
     

  • Dow

    33,800.60
    +297.03 (+0.89%)
     

  • Nasdaq

    13,900.19
    +70.88 (+0.51%)
     

  • BTC-INR

    4,455,961.50
    +81,345.50 (+1.86%)
     

  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     

  • Hang Seng

    28,698.80
    -309.27 (-1.07%)
     

  • Nikkei

    29,768.06
    +59.08 (+0.20%)
     

  • EUR/INR

    88.9028
    +0.0430 (+0.05%)
     

  • GBP/INR

    102.3868
    -0.0108 (-0.01%)
     

  • AED/INR

    20.2940
    +0.0390 (+0.19%)
     

  • INR/JPY

    1.4647
    +0.0019 (+0.13%)
     

  • SGD/INR

    55.7130
    +0.0690 (+0.12%)
     

Global Dental Hygiene Devices Market (2021 to 2025) - Featuring 3M, Brasseler and DentalEZ Among Others - ResearchAndMarkets.com

·3-min read

The "Global Dental Hygiene Devices Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The publisher has been monitoring the dental hygiene devices market and it is poised to grow by $1.23 billion during 2021-2025 progressing at a CAGR of 8% during the forecast period.

The report on dental hygiene devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing number of dental cases, product launches, and growing number of M&A for business expansion.

The dental hygiene devices market analysis includes product segment and geographical landscapes. This study identifies the growing focus on strategic partnerships as one of the prime reasons driving the dental hygiene devices market growth during the next few years. Also, technological advances in dental hygiene devices and rapid growth potential in emerging economies will lead to sizable demand in the market.

Companies Mentioned

  • 3M Co.

  • BIOLASE Inc.

  • Brasseler USA

  • COLTENE Holding AG

  • DentalEZ Inc.

  • DENTSPLY SIRONA Inc.

  • Envista Holdings Corp.

  • Hu-Friedy Mfg. Co. LLC

  • Komet USA LLC

  • Nakanishi Inc.

The report on dental hygiene devices market covers the following areas:

  • Dental hygiene devices market sizing

  • Dental hygiene devices market forecast

  • Dental hygiene devices market industry analysis

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Key Topics Covered:

1. Executive Summary

  • Market Overview

2. Market Landscape

  • Market ecosystem

  • Value chain analysis

3. Market Sizing

  • Market definition

  • Market segment analysis

  • Market size 2020

  • Market outlook: Forecast for 2020 - 2025

4. Five Forces Analysis

  • Five Forces Summary

  • Bargaining power of buyers

  • Bargaining power of suppliers

  • Threat of new entrants

  • Threat of substitutes

  • Threat of rivalry

  • Market condition

5. Market Segmentation by Product

  • Market segments

  • Comparison by Product

  • Dental handpieces - Market size and forecast 2020-2025

  • Dental burs - Market size and forecast 2020-2025

  • Dental lasers - Market size and forecast 2020-2025

  • Dental scalers - Market size and forecast 2020-2025

  • COVID-19 impact and recovery for the product segment

  • Market opportunity by Product

6. Customer Landscape

7. Geographic Landscape

  • Geographic segmentation

  • Geographic comparison

  • North America - Market size and forecast 2020-2025

  • Europe - Market size and forecast 2020-2025

  • Asia - Market size and forecast 2020-2025

  • ROW - Market size and forecast 2020-2025

  • Key leading countries

  • Market opportunity by geography

  • Volume drivers - Demand led growth

  • Market challenges

  • Market trends

8. Vendor Landscape

  • Overview

  • Vendor landscape

  • Landscape disruption

9. Vendor Analysis

  • Vendors covered

  • Market positioning of vendors

  • 3M Co.

  • BIOLASE Inc.

  • Brasseler USA

  • COLTENE Holding AG

  • DentalEZ Inc.

  • DENTSPLY SIRONA Inc.

  • Envista Holdings Corp.

  • Hu-Friedy Mfg. Co. LLC

  • Komet USA LLC

  • Nakanishi Inc.

10. Appendix

  • Scope of the report

  • Currency conversion rates for US$

  • Research methodology

  • List of abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/s2c01r

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005299/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Latest stories

  • COVID-19: Night curfew imposed in UP's Gorakhpur till April 18

    <p>Gorakhpur (UP), Apr 10 (PTI) The Gorakhpur district administration on Saturday decided to impose a night curfew till April 18 in the wake of rising coronavirus cases.</p>

  • Ligue 1: Kylian Mbappe strikes as PSG keep pressure on league toppers Lille

    This was Mbappe's 21st Ligue 1 goal of the season and his 33rd in all competitions in 39 games.

  • C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

    – CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – – CFT7455 Promotes Sustained Degradation of IKZF1/3 and Durable Anti-tumor Response, Including Regressions in an IMiD-Insensitive Myeloma Tumor Xenograft Model – – CFT7455 Phase 1/2 Trial in Multiple Myeloma and Non-Hodgkin Lymphomas On Track for 1H 2021 Initiation – WATERTOWN, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented preclinical data for CFT7455, the Company’s lead program, a MonoDACTM degrader targeting IKZF1/3 for the treatment of hematologic malignancies. These results, which support clinical evaluation of CFT7455 in multiple myeloma, were delivered as a late-breaking oral presentation during the first session of the American Association for Cancer Research (AACR) Annual Meeting 2021. “IKZF1/3 proteins are critical dependencies of B cell malignancies including multiple myeloma and subsets of non-Hodgkin’s lymphoma,” said Stewart Fisher, Ph.D., chief scientific officer of C4 Therapeutics. “We are pleased to share preclinical data demonstrating that potent catalytic IKZF1/3 degradation activity of CFT7455, coupled with optimized pharmacological properties, can result in regression of multiple myeloma xenograft tumors not responsive to approved IMiD therapies. We are optimistic that the in vitro and in vivo data we saw preclinically will translate into improved, clinically meaningful outcomes for patients and we look forward to initiating our CFT7455 Phase 1/2 clinical trial in the first half of this year.” Summary of Results C4T conducted in vitro studies to confirm CFT7455’s intended mechanism. Notable observations include: CFT7455 binds with high affinity to the E3 ligase adapter protein, cereblon (Kd = 0.9 nM);In vitro, CFT7455 treatment results in deep, rapid degradation of IKZF1/3 proteins, resulting in apoptotic cell death; andCFT7455 demonstrated broad, potent anti-proliferative activity in a panel of multiple myeloma cell lines. In mouse xenograft models of IMiD-insensitive multiple myeloma, data further established CFT7455 as a highly potent, catalytic degrader of IKZF1/3, capable of generating anti-tumor activity as a single agent and in combination with dexamethasone. Notable observations include: In the H929 myeloma xenograft tumor model, daily oral administration of CFT7455 at 0.1 mg/kg for three weeks led to partial or complete tumor regression, with the latter being durable even after stopping treatment.CFT7455 produced deep and durable degradation of IKZF3 in the RPMI-8226 myeloma xenograft tumor model, which is relatively insensitive to pomalidomide. Tumor regression resulted from treatment with CFT7455 in both naïve RPMI-8226 tumors, as well as those previously exposed, but unresponsive, to pomalidomide.The combination of CFT7455 and dexamethasone in the RPMI-8226 tumor xenograft model yielded expected improvements in efficacy and survival outcomes in mice bearing RPMI-8226 xenograft tumors, compared to either agent used alone. Based in part on these results, C4T plans to explore the therapeutic applications of CFT7455 for the treatment of relapsed or refractory multiple myeloma and non-Hodgkin’s lymphomas and expects to initiate a Phase 1/2 clinical study of CFT7455 in the first half of 2021. C4T’s AACR Annual Meeting 2021 presentation will be archived on the “Scientific Publications” page in the Investors section of the Company’s website, located at www.c4therapeutics.com. About CFT7455CFT7455 is an orally bioavailable MonoDAC™ (Monofunctional Degradation Activating Compound) degrader designed to bind with high affinity to the E3 ligase adapter protein, cereblon, to target and degrade IKZF1/3 for the treatment of hematologic malignancies such as multiple myeloma and non-Hodgkin’s lymphoma, including peripheral T cell lymphoma and mantle cell lymphoma. In preclinical studies, CFT7455 has demonstrated potent and selective protein degradation with favorable pharmacological properties. About C4 TherapeuticsC4 Therapeutics (C4T) is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.C4Therapeutics.com. Forward-Looking StatementsThis press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, express or implied statements regarding our ability to develop potential therapies for patients; the design and potential efficacy or safety profile of our therapeutic approaches; the potential timing, design and advancement of our preclinical studies and clinical trials, including the potential timing for regulatory authorization related to clinical trials; our ability and the potential to successfully manufacture and supply our product candidates for clinical trials; our ability to replicate results achieved in our preclinical studies or clinical trials in any future studies or trials; our current resources and cash runway; and regulatory developments in the United States and foreign countries. Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the initiation, timing and conduct of preclinical and clinical studies and other development requirements for our product candidates and the risk that the results of preclinical studies and/or clinical trials will or will not be predictive of future results in connection with future studies or trials. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in C4 Therapeutics’ most recent Annual Report on Form 10-K and/or Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and C4 Therapeutics undertakes no duty to update this information unless required by law. CONTACT: Investor & Media Contact Kendra Adams SVP, Communications & Investor Relations Kendra.Adams@c4therapeutics.com

  • ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Athenex, Inc. Investors to Secure Counsel Before Important May 3 Deadline – ATNX

    NEW YORK, April 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athenex, Inc. (NASDAQ: ATNX) between August 7, 2019 and February 26, 2021, inclusive (the “Class Period”), of the important May 3, 2021 lead plaintiff deadline. SO WHAT: If you purchased Athenex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 3, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience or resources. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020 founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the data included in the Oral Paclitaxel and Encequidar New Drug Application (“NDA”) presented a safety risk to patients in terms of an increase in neutropenia-related sequalae; (2) the uncertainty over the results of the primary endpoint of objective response rate (“ORR”) at week 19 conducted by blinded independent central review (“BICR”); (3) the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR; (4) Athenex’s Phase 3 study that was used to file the NDA was inadequate and not well-conducted in a patient population with metastatic breast cancer representative of the U.S. population, such that the FDA would recommended a new such clinical trial; (5) as a result, it was foreseeable that the FDA would not approve Athenex’s NDA in its current form; and (6) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Athenex class action, go to http://www.rosenlegal.com/cases-register-2051.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com cases@rosenlegal.com www.rosenlegal.com

  • Argentina's economy minister heads to Europe to woo finance officials over debts

    Argentine Economy Minister Martin Guzman will travel to Europe on Sunday to build support among G7 and G40 nations for a renegotiation of its multibillion-dollar debts to the International Monetary Fund (IMF) and the Paris Club group of creditor nations. Guzman will travel to Germany, France, Italy and Spain, where he will meet his counterparts and other officials to outline Argentina's restructuring plans during a five-day trip. "The objective is to get the necessary support from IMF shareholders (especially G7 and G20) to finalize a program that will serve Argentina," the Ministry of Economy said in a statement.

  • UP CM asks police force to forge direct link with masses

    <p>Lucknow, Apr 10 (PTI) Uttar Pradesh Chief Minister Yogi Adityanath on Saturday noted that the job of police is to forge a direct link with public, and that satisfaction of complainants is the parameter of success of the security personnel.</p>

  • Big Brother star Nikki Grahame dies aged 38

    The star, who appeared on the seventh series of Big Brother in 2006, had been fighting anorexia.

  • Djibouti's President Guelleh wins fifth term with 97% of votes

    Djibouti’s President Ismail Omar Guelleh won a fifth five-year term on Saturday after an election boycotted by most of the opposition, securing over 97% of the votes cast, official data from the Interior Ministry on Saturday showed. Friday's vote pitted only one challenger against the incumbent - relative newcomer Zakaria Ismail Farah. The Interior Ministry data showed that he came second with 2.48% of the 177,391 votes cast.

  • Soccer-Teenager Knauff bags first goal to give Dortmund 3-2 win at Stuttgart

    Borussia Dortmund teenager Ansgar Knauff fired in an 80th-minute winner for his first professional goal to give his team a 3-2 victory at VfB Stuttgart on Saturday and maintain their slim hopes of a top-four finish. Germany youth international Knauff, in his third league appearance, picked up the ball on the edge of the box and audaciously threaded his shot past two defenders and the goalkeeper to secure the win that lifted Dortmund to 46 points in fifth place. Eintracht Frankfurt are in fourth on 53 following their 4-3 win over third-placed VfL Wolfsburg, with six games left in the season and the top four finishers qualifying automatically for next season's Champions League group stage.

  • Bouquet-bearing public honors Philip, ignoring COVID warning

    British authorities have implored people to stay away from royal palaces as they mourn the death of Prince Philip in this time of COVID-19, but they keep coming. Not just to honor him, but to support Queen Elizabeth II, who lost her husband of 73 years. A cross-section of British society and admirers from abroad descended on Buckingham Palace and Windsor Castle on Saturday.

  • COVID-19: People without face masks will not be allowed to enter Mathura temples, says DM

    <p>Mathura, Apr 10 (PTI) Adhering to COVID-19 norms has been made mandatory for devotees visiting temples in Brijbhumi here amid rising coronavirus cases, officials said on Saturday.</p>

  • U.S. Army lieutenant files suit against two Virginia police for assault during traffic stop

    A U.S. Army lieutenant filed a lawsuit against two Virginia police officers in federal court over what court papers say was a violent traffic stop, where officers pointed their guns, knocked him to the ground, pepper sprayed him and "threatened to murder him." The suit, filed by Army officer Caron Nazario on April 2 in the U.S. District Court of Norfolk, Virginia, against Windsor policemen Joe Gutierrez and Daniel Crocker, alleges violations to his constitutional rights, and includes assault, illegal search and illegal detention. The incident captured on video comes at a time of heightened awareness over police arrests of minorities and racial justice, in the wake of the ongoing televised trial of former Minneapolis policeman Derek Chauvin following the death of George Floyd, a black man who died in police custody last May.

  • IPL 2021: MS Dhoni Is My Go To Man, I Go To Him If I Have Any Problem - Rishabh Pant

    Rishabh Pant said walking out for the toss with MS Dhoni as the opponent was a special feeling, calling the former India captain his 'go-to man'.

  • Kai Havertz stars as free-flowing Chelsea steamroller Crystal Palace

    Kai Havertz stars as free-flowing Chelsea steamroller Crystal Palace

  • UK passes 32m first Covid vaccination target figure days ahead of 15 April deadline

    Milestone passed as number of second jabs hits daily high

  • Pregnant Meghan Markle won’t travel to Prince Philip’s funeral on doctor’s advice, palace says

    It is understood Prince Harry will attend Saturday’s funeral

  • Happy That Prithvi Shaw’s Hard Work Is Paying Off: Shikhar Dhawan

    Shikhar Dhawan dazzled in Delhi Capitals’ IPL 2021 opener against the Chennai Super Kings as he made a whirlwind 85 to propel his side to a seven-wicket win. Shikhar Dhawan and Prithvi Shaw laid the foundation as Delhi Capitals were set to chase 189 by the Chennai Super Kings. The southpaw stressed on his partner Shaw’s innings, stating he was outstanding to watch. Delhi Capitals’ new-ball bowlers gave their side an incredible start by removing Faf Du Plessis and Ruturaj Gaikwad cheaply within the powerplay. But Suresh Raina was in fantastic touch as he added two quick-fire half-century stands with The post Happy That Prithvi Shaw’s Hard Work Is Paying Off: Shikhar Dhawan appeared first on CricketAddictor.

  • Benn vs Vargas - LIVE: Stream, latest updates and how to watch online

    The British welterweight battles the experienced Colombian as his incredible journey continues, while the undercard includes Savannah Marshall vs Maria Lindberg and Shannon Courtenay vs Ebanie Bridges

  • Soccer-Chelsea demolish Palace with Pulisic double

    LONDON (Reuters) -Chelsea roared back into fourth spot in the Premier League as Christian Pulisic scored twice in an impressive 4-1 victory at London rivals Crystal Palace on Saturday. After boss Thomas Tuchel's long unbeaten run since taking charge ended abruptly against West Bromwich Albion last week, Chelsea responded in emphatic fashion. Kai Havertz punished some sloppy defending to give Chelsea an eighth-minute lead and Pulisic doubled their advantage two minutes later with a powerful finish.